United States securities and exchange commission logo

                          August 23, 2022

       Adam Simpson
       Chief Executive Officer
       Icosavax, Inc.
       1930 Boren Avenue, Suite 1000
       Seattle, WA 98101

                                                        Re: Icosavax, Inc.
Statement on Form S-3
                                                            Filed August 16,
                                                            File No. 333-266894

       Dear Mr. Simpson:

              This is to advise you that we have not reviewed and will not
review your registration

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Doris
Stacey Gama at 202-551-3188 with any questions.


                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Cheston Larson, Esq.